This article reviews recent results of studies aiming to elucidate modes of integrating signals initiated in ACTH receptors and FGF2 receptors, within the network system of signal transduction found in Y1 adrenocortical cells. These modes of signal integration should be central to 
Introduction
Elucidation of the molecular mechanisms by which ACTH exerts its growth effects on adrenal cortex has defied investigators for decades. In the intact organism ACTH seems to be a mitogen, but in cultures of isolated adrenocortical cells ACTH behaves like a growth inhibitory hormone (1) .
In recent years, we have reported for the first time a weak mitogenic response elicited by pulses of ACTH in cultures of the mouse Y1 adrenocortical tumor cell line (2, 3) . An investigation of the pathways activated by the ACTH receptors to trigger this mitogenic response in the Y1 adrenocortical cell system is likely to yield results of interest to understand the reactions underlying the ACTH growth effects on adrenal cortex.
Considerable attention has been recently given to mitogenic effects triggered by peptide hormones that activate G protein-coupled receptors. The majority of these studies has centered on determining whether, and how, signals initiated in G protein-coupled receptors can activate the mitogen-activated protein kinase (MAPK) cascades, particularly the one including the class of the extracellular signal-regulated kinases (ERK-MAPK) (4) .
In Y1 adrenocortical cells, we started by showing that ACTH induces transcription of the fos and jun gene families (5,6), a characteristic of peptide growth factors that bind to tyrosine kinase receptors initiating signals to activate the ERK-MAPK pathway. The Fos and Jun protein families consist of four (cFos, FosB, Fra1 and Fra2) and three gene products (c-Jun, JunB and JunD), respectively, that dimerize via a leucine zipper domain to form hetero-(Fos-Jun) and homodimers (Jun-Jun), that comprise the series of transcription factors denominated AP1 (7). AP1 factors seem to play a critical role in the control of G 0 ®G 1 ®S transition of the cell cycle. Quiescent G 0 -arrested fibroblasts exhibit very low levels of AP1 factors and upon stimulation by peptide growth factors, like fibroblast growth factor 2 (FGF2), rapidly induce the fos and jun genes in an ordered fashion (7) . Blocking the induction of c-Fos and c-Jun proteins is sufficient to block the G 0 ®G 1 ®S transition in G 0 -arrested fibroblasts stimulated with FGF2 (8-10). Thus, ACTH, inducing the fos and jun genes in Y1 adrenocortical cells, resembles FGF2 triggering the G 0 ®G 1 ®S transition in G 0 -arrested 3T3 fibroblasts.
FGF2 is the prototype of the large family of fibroblast growth factors (11) , presently consisting of 18 members (12) that are widely expressed in embryo, fetus and adult tissues of vertebrates and invertebrates. It has been recognized for years that forms of FGF play key roles in mitogenesis, cellular differentiation, angiogenesis and repair of tissue injury in the adult organism (11) . In addition, reports of the last few years have involved molecular pathways commanded by FGFs in fundamental steps of embryo and fetal development such as left-right asymmetry determination in chick and mouse embryo (13) , hepatogenesis in mouse embryo (14) , development of the Drosophila tracheal system and the mouse lung (15) , and development of the rat exocrine pancreas (16) . In fact, it is becoming more and more clear that the FGF family of proteins and their respective set of receptors are major players governing the classical epithelial-mesenchymal interactions that underlie differentiation and organogenesis in the embryo. In the adult organism FGF forms persist throughout a number of different tissues as local paracrine and autocrine regulators of very basic biological processes like mitogenesis and cellular differentiation. The interaction between classical trophic hormones and FGFs, locally produced at the target cell level, is likely to be a major part of the molecular mechanisms by which trophic hormones regulate functions of target cells.
In adrenal cortex, FGF2 has long been considered a candidate for participating in the control of adrenal gland development in the fetus and also of growth and function in the adult adrenal cortex tissue (17) . In this article we present an overview of our recent work focusing on the interaction between ACTH and FGF2 in cell cycle control of the Y1 adrenocortical tumor cell line. Y1 adrenocortical tumor cells behave in many respects like normal adrenocortical cells and have long been used as a model adrenocortical cell system (18) . Particularly important is the fact that cultures of the Y1 clonal cell line are amenable to genetic approaches such as the classical somatic genetics (19) or the more recent DNA-mediated gene transfer approach (20) . Thus, the study of the interaction between ACTH and FGF2 in Y1 adrenocortical cells is timely and methodologically promising. Our aim is to elucidate modes of integrating signals initiated in ACTH receptors and FGF2 receptors within the network system of signal transduction found in Y1 adrenocortical cells. These modes of signal integration should be central to the mechanisms underlying the regulation of the G 0 ®G 1 ®S transition in the adrenal cell cycle. It is still unknown whether endogenous growth factors play an autocrine role in the growth control of Y1 adrenocortical cells. Nonetheless, total RNA of Y1 cells, probed with RT-PCR and specific primers, has yielded cDNA sequences of FGF2, FG5 and PDGF A, indicating that these peptide factors are produced by this adrenocortical cell line. In addition, serum-free medium conditioned with Y1 cells is rich in PDGF-like factors, but recombinant forms of PDGF AB and BB do not trigger a mitogenic response in G 0 /G 1 -arrested Y1 cells. Furthermore, Y1 cell lysates, but not serum-free conditioned medium, possess active FGF-like factors, suggesting that Y1 cells do not liberate this kind of factors into the culture medium.
FGF2 is a strong mitogen for Y1 adrenocortical cells

Short pulses of ACTH can elicit a weak mitogenic response in Y1 adrenocortical cells
Short pulses (up to 2 h) of synthetic ACTH 39 and natural porcine corticotropin A, at physiological concentrations, trigger DNA synthesis stimulation in G 0 /G 1 -arrested Y1 adrenocortical cells. In a 24-h experiment, a 2-h pulse of 1 nM ACTH 39 or 0.1 mU/ml corticotropin A respectively leads to a 2.6-and 2.5-fold increase in BrdU-labeling index; under the same conditions, 0.2 nM FGF2 causes a 7-fold increase in BrdUlabeling index. This mitogenic activity of ACTH is not dependent on the cAMP/PKA pathway, since it is observed in PKA-deficient mutants of the Y1 cell line. In addition, ACTH mitogenic activity is inhibited by the PKC inhibitor GF109203X. Thus, according to this mitogenic assay, ACTH resembles FGF2, except that ACTH is a weak mitogen (2, 3) .
The synthetic ACTH fragment 7-38, a well-known competitive inhibitor of ACTH 39 (21), at 100 nM inhibits by 60% and 80% the DNA synthesis respectively stimulated by 1 nM ACTH 39 and 1 mU/ml corticotropin A, indicating that this mitogenic effect of ACTH 39 and corticotropin A is mediated by specific ACTH receptors.
Two clear differences between the patterns of mitogenic activity of ACTH and FGF2 should be emphasized. First, experiments to define the dose-response relationship show a sharp difference between ACTH and FGF2: a bell-shaped curve for ACTH 39 with a maximum between 0.1 and 1 nM and an asymptotic curve in the range of 0.1 to 1000 pM for FGF2 with an ED50% of about 0.5 pM. Second, for ACTH, mitogenic activ-ity decreases sharply beyond 2 h of pulse length, whereas for FGF2, mitogenic activity is the same for short pulses or sustained treatment.
ACTH induces transcription of the
Similar results were obtained with FGF2 and PMA (phorbol-12-myristate-13-acetate) in identical experiments of run-off transcription. To further probe into fos and jun induction by signals initiated in ACTH receptors, we took the entire ACTH receptor cDNA, inserted it in the pSVK3 mammalian vector, and transfected it into Balb3T3 fibroblasts (22) . Stable 3T3 transfectants, expressing active ACTH receptors, respond to ACTH displaying induction of c-Fos, Fra1, Fra2, cJun and JunB proteins; circumstantial evidence suggests that this induction is independent of the cAMP/PKA pathway. Taken together, these results indicate that ACTH receptors can potentially initiate signals sufficient to induce the whole set of fos and jun genes.
On the other hand, ACTH, in contrast to FGF2, does not have any effect on transcription of the c-myc oncogene in Y1 adrenocortical cells. Thus, with respect to transcription induction of the early response genes, required for G 0 ®G 1 ®S transition, namely the fos, jun and c-myc genes, ACTH effects are not equal to FGF2 effects. In fact, ACTH post-transcriptionally inhibits the expression of c-myc induced by FGF2, by mechanisms dependent on cAMP/PKA (see below).
We should keep in mind that Y1 adrenocortical cells are tumor cells whose control of c-myc transcription is partially relaxed, due to amplification and over-expression of the c-Ki-ras proto-oncogene. For these reasons, Y1 cells serum starved to arrest the cell cycle show significantly high basal levels of c-myc expression, i.e., 20 to 30% nuclear labeling with anti-c-Myc antibodies. This conclusion is supported by transfections of the N17 dominant negative mutant of c-ras into Y1 adrenocortical cells that yields stable transfectants displaying a reconstituted tight control of c-myc expression.
c-Fos and c-Jun proteins are mediators of the mitogenic response to both ACTH and FGF2
To test whether fos and jun induction is necessary for cell entry into the S phase stimulated by ACTH and FGF2, we blocked c-Fos and c-Jun protein synthesis with antisense phosphorotioate oligodeoxynucleotides (23) .
The pattern of antisense inhibition is different for FGF2 and ACTH. Combination of both c-fos and c-jun antisense oligonucleotides is required to completely inhibit DNA synthesis stimulation by FGF2; c-fos or cjun oligonucleotide alone causes only about 50% inhibition. On the other hand, DNA synthesis stimulated by ACTH is essentially abolished by either c-fos or c-jun antisense oligonucleotides. In spite of these differences in patterns of antisense inhibition, altogether these results support the notion that the induction of c-Fos and c-Jun proteins is a necessary step in the triggering mechanisms by which both ACTH and FGF2 drive G 0 / G 1 -arrested Y1 adrenal cells to enter the S phase.
ACTH antagonizes the mitogenic action of FGF2
Analysis of the interaction between ACTH and FGF2 has revealed that ACTH antagonizes the mitogenic action of FGF2, On the other hand, ACTH 39 has no effect whatsoever on the induction of cyclin D1 protein by FGF2 in Y1 adrenocortical cells. Intriguingly, commercially available preparations of natural porcine corticotropin A (100 mU/ml; Sigma Chemical Co., St. Louis, MO, USA) block cyclin D1 induction when added together with FGF2 (1 nM) in a pulse of 1 h. But addition of the same preparation of corticotropin A (100 mU/ml) after the 1-h pulse of FGF2 (1 nM) has no effect on the induction of cyclin D1, detected by Western blot. Apparently, these commercial preparations of corticotropin A contain as a contaminant an unknown small peptide (or peptides) of pituitary origin and distinct from ACTH that blocks cyclin D1 induction by FGF2 in Y1 adrenocortical cells (see below). The phosphorylated forms of ERK1 and ERK2 are not detected in lysates of G 0 /G 1 -arrested Y1 cells by Western blots, developed with specific antibodies to both ERKphosphorylated forms. FGF2 and corticotropin A rapidly and transiently promote activation of both ERK-MAPK forms with similar kinetics: peaking between 2 and 5 min and sharply decreasing after 10 min ( Figure 1A ). cAMP analogs (0.5 to 3 mM) have no effect on ERK activation promoted by FGF2 (Figure 1A) . The synthetic forms of ACTH, ACTH 39 and ACTH 24 , do not duplicate the ERK-activating effect of corticotropin A (Figure 1C) , whereas PMA (10 ng/ml) and fetal calf serum (10%) promote maximal activation of both ERK1 and ERK2. This observation agrees with the report by Pestell and collaborators (24) Figure  1C ). These results imply that the most active chemical species in corticotropin A, that promotes ERK phosphorylation, is an unknown peptide different from ACTH 39 and ACTH 24 . On the other hand, corticotropin A does not promote phosphorylation of ERK in Balb3T3 fibroblasts, suggesting that the active species of corticotropin A are specific for adrenal cells. As expected, FGF2 is equally active in Y1 adrenocortical cells and Balb3T3 fibroblasts in promoting ERK phosphorylation.
ACTH is a poor activator of ERK-
One batch of a commercial preparation of porcine pituitary corticotropin A was fractionated on a reverse phase HPLC-column and analyzed by mass spectrometry and Nterminal sequencing. ACTH 39 , representing 40% of the total, is the major component and was isolated in a single homogeneous fraction (fraction 4). Other identified major components were ßMSH (fraction 3) and gMSH (fraction 2), which are not active on Y1 cells. Fraction 1 displays 6 peaks that were not chemically identified. Fraction 1 shows the highest activity for promotion of ERK-MAPK phosphorylation ( Figure 1B and C) and the lowest activity for steroidogenesis stimulation ( Table 1) .
The MEK inhibitor, PD98059 (50 µM), strongly inhibits ERK phosphorylation promoted by corticotropin A and PMA in Y1 adrenal cells. In addition, as expected, 50 µM PD98059 inhibits at least 80% of the DNA synthesis stimulated by 100 mU/ml corticotropin A. Unexpectedly, 50 µM PD98059 turns out to be also a strong inhibitor of both DNA synthesis stimulation and c-Fos induction by the synthetics ACTH 39 Steroidogenesis was estimated by extracting and assaying the fluorescent steroids liberated by cells into serum-free medium; specific activities were determined from dose-response curves. The unit of activity was arbitrarily defined as the ratio between fluorescence of stimulated cultures over fluorescence of untreated controls. Extracellular signal-regulated kinases-mitogen-activated protein kinases (ERK-MAPK) activation was assayed by Western blot as described in Figure 1 . c-Fos protein induction was estimated by immunocytochemical staining with anti-c-Fos antibodies counting % labeled nuclei under the microscope. All fractions significantly activated adenylate cyclase but specific activities were not determined. ACTH 39 (EPM) and ACTH 24 (EPM) are peptides synthesized in the laboratory of L. Juliano. ACTH 39 (Sigma) is a commercial product. Porcine corticotropin A batch 96H0687 was purchased from Sigma. All peptide fractions were chemically characterized by HPLC and mass spectrometry and also eventually by N-terminal sequencing. ND: Not determined. 
Conclusions
FGF2 elicits a prototypic mitogenic response in Y1 adrenocortical cells that cannot be triggered by signals initiated in ACTH receptors.
Taken together, the results reviewed here suggest that the weak mitogenic response of Y1 adrenocortical cells to ACTH, whose unmasking we recently reported (3), consists of the following sequential steps: a) initiation of signals in ACTH receptors, b) activation of PKC, c) activation of ERK-MAPK, d) induction of fos and jun genes, and e) stimulation of entry of G 0 /G 1 -arrested cells into the S phase of cell cycle.
Signals initiated in ACTH receptors and transduced by the cAMP/PKA pathway posttranscriptionally down-regulate c-Myc protein expression, typifying an efficient mechanism of growth inhibition.
We are still missing important links to explain the mechanisms that underlie the correlation between chronically elevated levels of circulating ACTH and, for instance, the adrenal cortex hyperplasia well documented in classical inborn errors of steroidogenesis (25) .
